tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Tianda Pharmaceuticals Reports Increased Losses in 2025 Interim Results

Story Highlights
Tianda Pharmaceuticals Reports Increased Losses in 2025 Interim Results

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Tianda Pharmaceuticals Ltd. ( (HK:0455) ) has issued an update.

Tianda Pharmaceuticals Ltd. reported its unaudited interim results for the first half of 2025, showing a decrease in revenue from HK$156,073,000 in 2024 to HK$136,635,000 in 2025. The company experienced a loss of HK$33,501,000 for the period, compared to a loss of HK$27,225,000 in the previous year, indicating challenges in maintaining profitability. Despite the financial losses, the company noted improvements in other comprehensive income, with a total comprehensive loss of HK$20,165,000, which is an improvement from the HK$41,924,000 loss in 2024.

More about Tianda Pharmaceuticals Ltd.

Tianda Pharmaceuticals Ltd. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on the development, manufacturing, and distribution of pharmaceutical products.

Average Trading Volume: 172,222

Technical Sentiment Signal: Hold

Current Market Cap: HK$387M

See more data about 0455 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1